Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PediLact in Neonatal Hyperbilirubinemia
NCT03266913Phase 3Unknown
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of PediLact in neonatal hyperbilirubinemia (2 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoint: Duration of phototherapy at 6 days. Status: unknown.
02
Drugs
PediLact
03
Conditions
neonatal hyperbilirubinemia
Beyond the preview
Go deeper on NCT03266913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266913.